BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

...year amid that company’s $340 million acquisition by Pfizer Inc. (NYSE:PFE), VectivBio is developing apraglutide, a GLP-2...
...apraglutide.The company believes apraglutide could be a best-in-class therapy. The once-weekly injection would compete with GLP-2...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

...By Claire Quang, Staff Writer DISEASE CATEGORY: Endocrine/metabolicINDICATION: Diabetes; obesityA fusion protein comprising FGF21 and GLP-1...
...diabetes and obesity. In HEK cells, the fusion protein agonized the FGF21 receptor complex and GLP-1R...
...compared with FGF21 or GLP-1 monotherapy.TARGET/MARKER/PATHWAY: Fibroblast growth factor 21 (FGF21); glucagon-like peptide-1 (GLP-1); glucagon-like peptide-1 receptor (GLP-1R...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

...In HEK cells and a human colon cell line, cholic acid-7-sulfate activated GPBAR1 and induced GLP-1...
...bowel disease and non-infectious diarrhea.TARGET/MARKER/PATHWAY: G protein-coupled bile acid receptor 1 (GPBAR1; TGR5); glucagon-like peptide-1 (GLP-1)EXPERIMENTAL...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...Phase I/II trials for peptide-small molecule hybrid GLP-1R/GIPR...
...to read out next year, follow first-in-class GLP-1R/GIPR...
...the mechanism of action of the natural GLP-1...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

...five obesity programs, Novo pins hopes on amylin/GLP-1...
...the company is focusing on the once-weekly GLP-1...
...and GLP-1 co-agonist. The latter is a glucagon/GLP-1/GIP...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

...suggesting that their launched may hit harder. She noted that the launch of the oral GLP-1...
...TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 CGRP - Calcitonin gene-related peptide GLP-1...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

...Lin said the 52-week data looked “better than any oral drug except for the oral GLP-1”...
...not stand out from the 0.3-0.7% and 0.6-1.16% placebo- or control-adjusted reductions reported for marketed GLP-1R...
...depression, anxiety and Fragile X syndrome. Targets GCK (GK) - Glucokinase GLP-1 - Glucagon-like peptide-1 (GLP-1...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

...that although ziltivekimab is Novo Nordisk’s first dedicated clinical asset for atherosclerosis, it has tested GLP-1...
...“Nearing Threshold to Replace Gastric Bypass” ). Since FDA’s first approval of the subcutaneous GLP-1...
...last year as Rybelsus. Targets APOCII (APOC2) - Apolipoprotein C-II APOCIII (APOC3) - Apolipoprotein C-III GLP-1...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...KT-A832, which encodes IGF-1 and is delivered by intrapancreatic injection; or KT-Af22, which encodes a GLP-1R...
...Asia Alpha and Transhuman Capital CEO: Shankar Ramaswamy Patents: Undisclosed Targets GCK (GK) - Glucokinase GLP-1R...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...20, escalating doses up to 2.4 mg once weekly of the long-acting glucagon-like peptide-1 receptor (GLP-1R...
...see “ Novo’s Year of Obesity ” ). Novo already markets Saxenda -- the only GLP-1R...
... Sandi Wong, Assistant Editor Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Novo Nordisk A/S Glucagon-like peptide-1 receptor (GLP-1R...
Items per page:
1 - 10 of 1313